Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1948 1
1950 2
1951 3
1952 3
1953 3
1954 5
1955 8
1956 8
1957 11
1958 9
1959 18
1960 10
1961 9
1962 9
1963 12
1964 9
1965 10
1966 8
1967 4
1968 9
1969 7
1970 8
1971 4
1972 3
1973 7
1974 4
1975 8
1976 17
1977 17
1978 20
1979 10
1980 13
1981 12
1982 12
1983 26
1984 24
1985 23
1986 32
1987 22
1988 29
1989 35
1990 31
1991 28
1992 30
1993 33
1994 25
1995 23
1996 35
1997 33
1998 41
1999 28
2000 35
2001 35
2002 25
2003 27
2004 29
2005 39
2006 36
2007 37
2008 30
2009 23
2010 33
2011 35
2012 44
2013 54
2014 57
2015 77
2016 69
2017 84
2018 84
2019 94
2020 84
2021 76
2022 68
2023 31

Text availability

Article attribute

Article type

Publication date

Search Results

1,860 results

Results by year

Filters applied: . Clear all
Page 1
Environment dominates over host genetics in shaping human gut microbiota.
Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, Shilo S, Lador D, Vila AV, Zmora N, Pevsner-Fischer M, Israeli D, Kosower N, Malka G, Wolf BC, Avnit-Sagi T, Lotan-Pompan M, Weinberger A, Halpern Z, Carmi S, Fu J, Wijmenga C, Zhernakova A, Elinav E, Segal E. Rothschild D, et al. Among authors: wolf bc. Nature. 2018 Mar 8;555(7695):210-215. doi: 10.1038/nature25973. Epub 2018 Feb 28. Nature. 2018. PMID: 29489753
Personalized Postprandial Glucose Response-Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes.
Ben-Yacov O, Godneva A, Rein M, Shilo S, Kolobkov D, Koren N, Cohen Dolev N, Travinsky Shmul T, Wolf BC, Kosower N, Sagiv K, Lotan-Pompan M, Zmora N, Weinberger A, Elinav E, Segal E. Ben-Yacov O, et al. Among authors: wolf bc. Diabetes Care. 2021 Sep;44(9):1980-1991. doi: 10.2337/dc21-0162. Epub 2021 Jul 23. Diabetes Care. 2021. PMID: 34301736 Clinical Trial.
Dimethylcalcium.
Wolf BM, Stuhl C, Maichle-Mössmer C, Anwander R. Wolf BM, et al. J Am Chem Soc. 2018 Feb 14;140(6):2373-2383. doi: 10.1021/jacs.7b12984. Epub 2018 Feb 5. J Am Chem Soc. 2018. PMID: 29328671
Effects of personalized diets by prediction of glycemic responses on glycemic control and metabolic health in newly diagnosed T2DM: a randomized dietary intervention pilot trial.
Rein M, Ben-Yacov O, Godneva A, Shilo S, Zmora N, Kolobkov D, Cohen-Dolev N, Wolf BC, Kosower N, Lotan-Pompan M, Weinberger A, Halpern Z, Zelber-Sagi S, Elinav E, Segal E. Rein M, et al. Among authors: wolf bc. BMC Med. 2022 Feb 9;20(1):56. doi: 10.1186/s12916-022-02254-y. BMC Med. 2022. PMID: 35135549 Free PMC article. Clinical Trial.
Prediction models of treatment response in lupus nephritis.
Ayoub I, Wolf BJ, Geng L, Song H, Khatiwada A, Tsao BP, Oates JC, Rovin BH. Ayoub I, et al. Among authors: wolf bj. Kidney Int. 2022 Feb;101(2):379-389. doi: 10.1016/j.kint.2021.11.014. Epub 2021 Dec 3. Kidney Int. 2022. PMID: 34871620 Free PMC article.
S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms.
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. Sabrina V, et al. Among authors: wolf b. Z Gastroenterol. 2022 Jan;60(1):e56-e130. doi: 10.1055/a-1589-7568. Epub 2022 Jan 18. Z Gastroenterol. 2022. PMID: 35042248 Free article. German. No abstract available.
S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL.
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. Sabrina V, et al. Among authors: wolf b. Z Gastroenterol. 2022 Jan;60(1):81-107. doi: 10.1055/a-1589-7520. Epub 2022 Jan 18. Z Gastroenterol. 2022. PMID: 35042249 Free article. German. No abstract available.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: wolf bb. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV. Piotrowska Z, et al. Among authors: wolf b. Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26. Cancer Discov. 2018. PMID: 30257958 Free PMC article.
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Subbiah V, et al. Among authors: wolf b. Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15. Cancer Discov. 2018. PMID: 29657135
1,860 results